Korten V, Erdem I, Murray B E
Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey.
Diagn Microbiol Infect Dis. 1996 Oct;26(2):79-85. doi: 10.1016/s0732-8893(96)00197-6.
The in vitro activity of DU-6859a (DU) alone and in combination with various antimicrobials was evaluated against multiresistant enterococci including some isolates with defined gyrA mutations. DU produced rapid in vitro killing against most enterococci that lacked resistance to ciprofloxacin, but it was not bactericidal against strains with MICs of ciprofloxacin of > or = 8 micrograms/ml, or against one of four strains with an MIC of ciprofloxacin of 4 micrograms/ml. The combination of DU with rifampin was antagonistic against two of two isolates tested. Combinations of DU and novobiocin, gentamicin, or a beta-lactam (amoxicillin, ampicillin-sulbactam, or amoxicillin-clavulanate) were generally indifferent. When different beta-lactams were used together, with or without DU, bactericidal activity was observed against some isolates. Despite the absence of synergistic interactions with other agents, DU is a promising fluoroquinolone for use against enterococci, although prior development of resistance to currently available fluoroquinolones diminishes some of its effect.
评估了DU-6859a(DU)单独以及与多种抗菌药物联合使用时对多重耐药肠球菌的体外活性,其中包括一些具有明确gyrA突变的分离株。DU对大多数对环丙沙星敏感的肠球菌具有快速的体外杀菌作用,但对环丙沙星MIC≥8微克/毫升的菌株,或对环丙沙星MIC为4微克/毫升的四株菌株中的一株没有杀菌作用。DU与利福平联合使用对两株受试分离株中的两株具有拮抗作用。DU与新生霉素、庆大霉素或β-内酰胺类药物(阿莫西林、氨苄西林-舒巴坦或阿莫西林-克拉维酸)联合使用通常无相互作用。当不同的β-内酰胺类药物一起使用时,无论是否有DU,对一些分离株都观察到了杀菌活性。尽管与其他药物没有协同相互作用,但DU是一种有前景的用于对抗肠球菌的氟喹诺酮类药物,尽管先前对现有氟喹诺酮类药物产生的耐药性会削弱其部分效果。